Product Description
CBT-501 is a novel IgG4 humanized monoclonal antibody against the Programmable Death-1 (PD-1) membrane receptor on immune cells. (Sourced from: https://www.apollomicsinc.com/media/cbt-pharmaceuticals-initiates-phase-1b-clinical-trial-for-anti-pd-1-antibody-cbt-501-01-genolimzumab-injection-in-patients-with-advanced-solid-tumors/)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Apollomics
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatocellular Carcinoma|Renal Cell Carcinoma
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03053466 |
APL-501-01 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2022-02-25 |
50% |
2022-05-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03655613 |
APOLLO | P2 |
Terminated |
Hepatocellular Carcinoma|Renal Cell Carcinoma |
2021-12-15 |
7% |
2022-05-07 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |